ECS Botanics has entered into a binding offtake agreement with UK-based medicinal cannabis distributor Rokshaw to supply dried flower.
The three-year contract requires ECS to supply at least 600kg of pharmaceutical-grade flower annually, with deliveries beginning during the current growing season. The deal is expected to generate A$9.3 million for the company.
The agreement follows a series of recent deals with MediCann Health, Entoura and Precision Pharmaceuticals.
Rokshaw operates under the umbrella of Canadian-listed Curaleaf International and supplies a range of flower and oil products across the UK market.
ECS managing director Nan-Maree Schoerie described the deal as "another substantial milestone with a new international customer" and said the company had now executed offtake agreements totalling $60m over the past 18 months.
She added: "We are well positioned to meet the increasing demand and fulfill orders efficiently. This is attributed to the recent expansion of our cultivation areas and yield improvements from our R&D initiatives, both playing a key role in enabling us to significantly boost production."
Rokshaw managing director Richard Hodgson said the partnership reaffirmed the company's commitment to broadening access in the UK, "with competitively priced products with a variety of strain profiles and dosage forms."
He added: "ECS stood-out as a producer that we really wanted to work with, so we are extremely excited that we have been able to make this happen, and we look forward to seeing how our partnership develops."
Separately, ECS informed the ASX that its GMP-certified THC pastilles (gummies), distributed through client Entoura since their late-2023 launch, have seen strong customer demand.
The company said the rapid allocation of the initial shipment pointed to significant appetite in Australia for alternative dosage forms.
ECS Botanics was a three-time winner at the The Cannabis Observer Awards 2023.
